12.20-001

ITW

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. Application Number 10/776,934 Filing Date TRANSMITTAL February 10, 2004 First Named Inventor **FORM** Bo Hansen Art Unit 1614 (to be used for all correspondence after initial filing) Examiner Name Not Yet Assigned Attorney Docket Number 58610(71432) Total Number of Pages in This Submission ENCLOSURES (Check all that apply) After Allowance Communication Fee Transmittal Form Drawing(s) Appeal Communication to Board of Fee Attached Licensing-related Papers Appeals and Interferences Appeal Communication to TC Petition Amendment/Reply (Appeal Notice, Brief, Reply Brief) Petition to Convert to a After Final Proprietary Information **Provisional Application** Power of Attorney, Revocation Affidavits/declaration(s) Status Letter Change of Correspondence Address Other Enclosure(s) (please **Extension of Time Request** Terminal Disclaimer Identify below): Return Receipt Postcard Express Abandonment Request Request for Refund x Information Disclosure Statement CD, Number of CD(s) Certified Copy of Priority Landscape Table on CD Document(s) Reply to Missing Parts/ Remarks Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name **EDWARDS & ANGELL, LLP** Signature Chin C.h

| | ence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 517 916 832 Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below. |
|--------------------------|---|
| Dated: December 16, 2004 | Signature Signature (Elisabeth Dunkle) |

Reg. No.


38,256

Printed name

Date

Christine C. O'Day

December 16, 2004



Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. EV 517 916 832 US in an envelope addressed to:

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

on December 16, 2004
Date

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Transmittal (1 page)

Supplemental Information Disclosure Statement IDS (Citation) by Applicant (8 References)

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 517 916 832 US, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313 1450, on the date shown below.

Dated: December 16, 2004 Signature:

Docket No.: 58610(71432)

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Bo Hansen et al.

Application No.: 10/776,934

Confirmation No.:

Filed: February 10, 2004

Art Unit: 1614

For:

OLIGOMERIC COMPOUNDS FOR THE

MODULATION OF SURVIVIN

EXPRESSION

Examiner: Not Yet Assigned

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

In accordance with 37 CFR 1.97, Applicant(s) hereby make of record the following additional documents. A PTO Form SB/08 and a full copy of each of the documents required under 37 CFR 1.98(a)(2) accompany this statement.

Applicant(s) have become aware of the following documents, cited in an International Search Report issued October 12, 2004, during the prosecution of a corresponding international application. A first office action has yet to issue in the above-referenced U.S. application. Thus, in accordance with 37 CFR 1.97(b) or in the alternate 1.97(e)(1), Applicants hereby submit(s) these documents for the Examiner's consideration.

This statement is not to be interpreted as a representation that the cited documents are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any document herein be construed per se as a representation that such document is prior art. Moreover,

Applicant(s) understand(s) the Examiner will make an independent evaluation of the cited documents.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 04-1105, under Order No. 58610(71432). A duplicate copy of this paper is enclosed.

Dated: December 16, 2004 Respectfully submitted,

By Church Christine C. O'Day

Registration No.: 38,256 EDWARDS & ANGELL, LLP

P.O. Box 55874 Boston, 02205 (617) 439-4444

Attorney for Applicant

PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are requi

DEC 1 6 2004 THE MANE IN Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 1

| Complete if Known | | | |
|------------------------|-------------------|--|--|
| Application Number | 10/776,934 | | |
| Filing Date | February 10, 2004 | | |
| First Named Inventor | Bo Hansen | | |
| Art Unit | 1614 | | |
| Examiner Name | Not Yet Assigned | | |
| Attorney Docket Number | 58610 (71432) | | |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|--------------|--|--------------------------------|--|---|
| Examiner Initials* | Cite No.1 | Document Number Number-Kind Code ² (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | AA | US-2002/0137708A1 | 09-26-2002 | | |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|--------------|---|-----------------------------------|--|---|----|
| Examiner Initials* | Cite No.1 | Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (<i>if known</i>) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T⁵ |
| | BA | WO-01/48190 A2 | 07-05-2001 | | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ** CITE NO.: Those document(s) which are marked with an double asterisk (**) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filling date under 35 U.S.C. 120. 'Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

| NON PATENT LITERATURE DOCUMENTS | | | | |
|---------------------------------|--------------|---|----|--|
| Examiner Initials | Cite No.1 | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T² | |
| | CA | S.L. Shankar et al., "Journal of Neurochemistry", Vol. 79, pp. 426-436, (2001) | | |
| | СВ | D. Grossman et al., " J. Invest. Dermatol.", Vol. 113, No. 6, pp. 1076-1081, (1999) | | |
| | CC | J. Kurreck et al., "Nucleic Acids Research", Vol. 30, No. 9 pp. 1911-1918, (2002) | | |
| | CD | K. Morita et al., "Bioorganic & Medicinal Chemistry Letters", Vol. 12, pp.73-76, (2002) | | |
| | CE | K.H. Altmann et al., "Applied Antisense Oligonucleotide Technology", Chapter 4, pp. 73-107, (1998) | | |
| | CF | A.S. Rait et al., "Cancer Gene Therapy", Vol. 8, No. 10, pp. 728-739, (2001) | | |

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ** CITE NO.: Those document(s) which are marked with an double asterisk (**) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120.

| Examiner | Date | |
|-----------|------------|-------------|
| Signature | Considered | |
| | | |

^{&#}x27;Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.